- Home
- GNPX vs ONFO Comparison
GNPX vs ONFO Comparison
Compare GNPX & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- ONFO
- Stock Information
- Founded
- GNPX 2009
- ONFO 2018
- Country
- GNPX United States
- ONFO United States
- Employees
- GNPX N/A
- ONFO N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- GNPX Health Care
- ONFO Technology
- Exchange
- GNPX Nasdaq
- ONFO Nasdaq
- Market Cap
- GNPX 6.2M
- ONFO 5.8M
- IPO Year
- GNPX 2018
- ONFO 2022
- Fundamental
- Price
- GNPX $0.27
- ONFO $1.09
- Analyst Decision
- GNPX Strong Buy
- ONFO
- Analyst Count
- GNPX 1
- ONFO 0
- Target Price
- GNPX $10.00
- ONFO N/A
- AVG Volume (30 Days)
- GNPX 7.3M
- ONFO 57.5K
- Earning Date
- GNPX 05-13-2025
- ONFO 04-16-2025
- Dividend Yield
- GNPX N/A
- ONFO N/A
- EPS Growth
- GNPX N/A
- ONFO N/A
- EPS
- GNPX N/A
- ONFO N/A
- Revenue
- GNPX N/A
- ONFO $7,862,077.00
- Revenue This Year
- GNPX N/A
- ONFO N/A
- Revenue Next Year
- GNPX N/A
- ONFO N/A
- P/E Ratio
- GNPX N/A
- ONFO N/A
- Revenue Growth
- GNPX N/A
- ONFO 50.04
- 52 Week Low
- GNPX $0.22
- ONFO $0.49
- 52 Week High
- GNPX $4.09
- ONFO $1.88
- Technical
- Relative Strength Index (RSI)
- GNPX 44.92
- ONFO 51.08
- Support Level
- GNPX $0.23
- ONFO $1.05
- Resistance Level
- GNPX $0.44
- ONFO $1.14
- Average True Range (ATR)
- GNPX 0.04
- ONFO 0.09
- MACD
- GNPX 0.00
- ONFO 0.02
- Stochastic Oscillator
- GNPX 26.65
- ONFO 70.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.